Abstract. The function of choline kinase (CK) and ethanolamine kinase (EK) is to catalyse the phosphorylation of choline and ethanolamine, respectively, in order to yield phosphocholine (PCho) and phosphoethanolamine (PEtn). A high expression level of PCho, due to elevated CK activity, has previously been associated with malignant transformation. In the present study, a quantitative polymerase chain reaction was performed to determine the mRNA expression profiles of ck and ek mRNA variants in MCF7 breast, HCT116 colon and HepG2 liver cancer cells. The ck and ek mRNA expression profiles showed that total ckα was expressed most abundantly in the HepG2 cells. The HCT116 cells exhibited the highest ckβ and ek1 mRNA expression levels, whereas the highest ek2α mRNA expression levels were detected in the MCF7 cells. The ckβ variant had higher mRNA expression levels, as compared with total ckα, in both the MCF7 and HCT116 cells. Relatively low ek1 mRNA expression levels were detected, as compared with ek2α in the MCF7 cells; however, this was not observed in the HCT116 and HepG2 cells. Notably, the mRNA expression levels of ckα2 were markedly low, as compared with ckα1, in all three cancer cell lines. The effects of epigenetic modification on ck and ek mRNA expression, by treatment of the cells with the histone deacetylase inhibitor trichostatin A (TSA), were also investigated. The results of the present study showed that the mRNA expression levels of ckα, ckβ and ek2α were affected by TSA. An increase >8-fold was observed in ek2α mRNA expression upon treatment with TSA, in a concentration-and time-dependent manner. In conclusion, the levels of ck and ek transcript variants in the three cancer cell lines were varied. The effects of TSA treatment on the mRNA expression levels of ck and ek imply that ck and ek mRNA expression may be regulated by epigenetic modification.
Introduction
Choline kinase (CK) and ethanolamine kinase (EK) are enzymes that initiate the first step in the Kennedy pathway, resulting in the biosynthesis of phosphatidylcholine and phosphatidylethanolamine (1) . In the presence of Mg 2+ , CK and EK catalyse the ATP-dependent phosphorylation of choline and ethanolamine into phosphocholine (PCho) and phoshoethanolamine (PEtn), respectively. In humans, CK is encoded by two separate genes, ckα and ckβ, which are located on chromosomes 11q13.2 and 23q13.33 (Ensembl Genome Browser v48, Gene view: http://www.ensembl.org/), respectively. The ckα transcript has been shown to undergo alternative splicing, resulting in the generation of two mRNA splice variants: ckα1 (NCBI reference: NM_212469.1) and ckα2 (NCBI reference: NM_001277.2). These splice variants are later translated into two functional protein isoforms, CKα1 and CKα2, consisting of 439 and 457 amino acids, respectively (2) . The ckα2 variant contains an additional stretch of 54 nucleotides, as compared with the ckα1 variant. CKβ is translated from the ckβ (NCBI reference: NM_005198.4) mRNA transcript, and consists of 395 amino acids and the protein sequence has 60% homology with the CKα1 and CKα2 isoforms (2) . Mammalian CKβ was initially characterised in rat liver (3) . In humans and mice, CKβ, alongside muscular carnitine-palmitoyl transferase 1b (M-CPT1b), are encoded by a bicistronic gene (4) . Due to the overlapping of the ckβ and m-cpt1b genes on the chromosome; therefore, Yamazaki et al (5) previously suggested that these two genes may share the same regulators.
Human EK exists as three isoforms: EK1, EK2α and EK2β, encoded by two separate genes; ek1, which produces the ek1 transcript variant 1 (NCBI reference: NM_018638.4); and ek2, which undergoes alternative splicing to produce ek2α (NCBI reference: NM_018208.2) and ek2β (GenBank reference: AK001623.1) transcript variants. ek2α and ek2β are respectively translated into EK2α and EK2β (6) .
Expression profiling of choline and ethanolamine kinases in MCF7, HCT116 and HepG2 cells, and the transcriptional regulation by epigenetic modification
CK actively participates in cell proliferation, which is modulated by various kinases and metabolites derived from phospholipids. PCho is a crucial lipid metabolite associated with cell proliferation and tumor development. Previously, a significant increase in CK activity and elevation of PCho levels was shown to be associated with cancer progression (7) . Malignant transformation and progression have previously been reported to alter phospholipid metabolism, by increasing the production of PCho (8, 9) . A high concentration of PCho is a common characteristic of tumor-derived cells, and may be used as a novel biomarker for cancer diagnosis and assessment of cancer progression (10, 11) . CKα has also been proposed as a potential prognostic marker, to predict the outcome in patients with non-small-cell lung cancer (12) .
The aim of the present study was to determine and analyze the expression profiles of ck and ek mRNA variants in MCF7 breast, HCT116 colon and HepG2 liver cancer cells, using quantitative polymerase chain reaction (qPCR). The cell lines were chosen due to the previously reported differential expression of CKα in breast, colon and liver tissues (13) . Although ckα overexpression is usually associated with carcinogenesis (12, 14) , it remains unclear whether this is always the case, as CKα protein expression levels have shown significant variation in numerous tumour tissues (13) . The expression levels of ckβ, relative to ckα, have also been shown to affect the regulation of the cell cycle (15) . Similarly, EK, which belongs to the same family of enzymes as CK, has been suggested to have a role in carcinogenesis, by promoting the growth of transformed cells (16) . However, the expression levels of the ek gene transcripts in various cancer cells have not yet been compared. Quantification of ck and ek expression levels in numerous cancer cells may provide a new insight into their roles in promoting cancer cell growth. In addition, the regulation of ck and ek transcriptional activities in cancer cells by epigenetic modification remains to be elucidated. Epigenetic modification, such as histone deacetylation, modulates the expression of numerous genes at the transcriptional level, including genes that encode tumor protein p53 (17, 18) , E2F (19) and nuclear factor-κB (19, 20) . Numerous histone deacetylase inhibitors (HDACi) have been synthesised, including trichostatin A (TSA), which belongs to the hydroxamic acids group. HDACi have been shown to regulate gene transcription by inducing histone acetylation, and modulating the recruitment of transcription factors and other proteins to the promoter region of target genes (21) . Notably, HDACi has also been reported to display significant demethylating activity by indirectly altering DNA and histone methylation (22) . TSA has been demonstrated to indirectly induce gene promoter demethylation in fungi (23) . To investigate whether the expression levels of ck and ek transcripts are affected by DNA methylation, a qPCR analysis was performed to determine the effects of TSA treatment in HepG2 cells. (24) . The TSA was dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich) and diluted in fresh medium. The control well was seeded with the same cellular density and treated with DMSO diluted with phosphate-buffered saline. To determine the effects of TSA concentration and treatment duration on ek2α expression levels, the HepG2 cells were treated with the indicated doses of TSA for 24 h, and at the indicated treatment durations with 750 nM TSA. The cells were observed using an inverted microscope (Leica Microsystems GmbH, Wetzlar, Germany).
Materials and methods

Cell
Total cellular RNA extraction and cDNA synthesis. Total RNA was extracted using the RNeasy Mini kit (Qiagen, Hilden, Germany). RNase-Free DNase I (Qiagen) was used to eliminate any contaminating genomic DNA. The yield and purity of the total RNA was assessed by measuring the absorbance at 260 nm using a BioPhotometer Plus (Eppendorf, Hamburg, Germany). The integrity and size distribution of the total RNA were examined by a 1% agarose gel electrophoresis. cDNA was reverse transcribed from 1 µg of total RNA, using the RevertAid TM H Minus First Strand cDNA Synthesis kit (Thermo Fisher Scientific, Waltham, MA, USA).
Preparation of plasmids as homologous standards for qPCR.
Plasmids containing the coding sequences of the various CK and EK isoforms (pET14b-ckα, pGEXRB-ckα2, pET14b-ckβ, pET14b-ek1, pMALK4-ek2α, and pGEXRB-ek2β) were used as standards for the qPCR. The plasmid copy number (PCN) was calculated using the following equation, as described by previous methods (25) :
A 10-fold serial dilution of each plasmid DNA, ranging from 1 x 10 2 to 1 x 10 7 copies/µl, was used to construct a standard curve. The PCR amplification efficiency of each gene was calculated from the corresponding standard curve using the following equation, as described previously (24):
qPCR. A qPCR was performed using the ABI PRISM 7000 Sequence Detection system (Applied Biosystems Life Technologies, Foster City, CA, USA). Each reaction was performed in a 25 µl volume containing 12.5 µl Power SYBR ® Green I Master Mix (Applied Biosystems), specific primer (300 nM of target primer or 1 µl of reference primer) and 1 µl template DNA (1:2 diluted cDNA or plasmid DNA dilutions ranging from 1x10 2 to 1x10 7 copies/µl). The specific primer sets for total-ckα, ckα2, ckβ, ek1, ek2α and ek2β (Table I) were designed to span intron-exon boundaries using in silico PCR and Primer-BLAST (National Institutes of Health, Bethesda, MA, USA). The reference genes used for relative quantification were UBC and YWHAZ. The reference gene primers were purchased from TATAA Biocenter (Göteburg, Sweden). The calculation used to determine the normalised relative quantities was previously described by Hellemans et al (26) . Thermal cycling was performed using the default settings of the ABI PRISM 7000 SDS software 1.0, as follows: 2 min at 50˚C, 10 min at 95˚C, followed by 40 cycles of 10 sec at 95˚C and 1 min at 60˚C. A melt curve analysis was performed immediately following the amplification, with temperatures ranging between 60 and 95˚C in 0.1˚C increments, in order to verify the PCR specificity. Absolute quantification of YWHAZ was also performed for the control and TSA-treated cells in the experiments involving TSA. YWHAZ was included as a control to account for possible variations in overall gene expression levels as a result of TSA treatment.
Identification of CpG islands in the gene promoter region.
The location of CpG islands at the ckα, ckβ, ek1 and ek2 promoter regions were determined using CpG Plot, which is available from the European Molecular Biology Open Software Suite (http://www.ebi.ac.uk/emboss/cpgplot). A CpG island is defined as a region of >200 bp nucleotides, with a GC content >50% and an observed/expected ratio >0.6.
Statistical analysis. Statistical evaluations were performed using a paired t-test and a one-way analysis of variance with the Tukey Honestly Significant Difference post-hoc test. All analyses were performed using SPSS version 18.0 (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.
Results
Expression profiling of ck and ek mRNA variants in MCF7, HCT116 and HepG2 cells.
In the present study, both absolute and relative quantification strategies were used to quantify and compare the mRNA expression levels of ck and ek variants in MCF7, HCT116 and HepG2 cells. The specificity of the PCR amplification of ck and ek variants was confirmed using a melt curve analysis and agarose gel electrophoresis. The slope of the generated standard curves for all of the amplicons was between -3.2 and -3.6, confirming that the amplifications were highly efficient.
The comparative cycle threshold (C t ) method was used to determine the expression levels of total-ckα, ckα2, ckβ, ek1, ek2α and ek2β variants, relative to the MCF7 cells and normalised to the geometric means of UBC and YWHAZ (Fig. 1A) . A previous study identified UBC and YWHAZ as the most suitable reference genes for normalisation in gene expression studies using MCF7, HCT116 and HepG2 cells (27) . In addition, an absolute mRNA copy number of each ck and ek variant was calculated from respective standard curves (Fig. 1B) . The ckα gene, which has previously been reported to be associated with carcinogenesis (7), had the highest mRNA expression levels detected in the HepG2 cells; total-ckα had a value of 2031±415.78 mRNA copies/ng total RNA. The highest mRNA expression levels of ckβ and ek1, were found in the HCT116 cells. The expression levels, relative to the MCF7 cells, were ~2-and 4-fold higher, respectively (Fig. 1A) . The absolute copy numbers of the ckβ and ek1 mRNA variants in the HCT116 cells, however, as determined by absolute quantification, were markedly lower. The ek2α variant displayed the highest mRNA expression levels in the MCF7 cells. ckα2 and ek2β, which are splice variants of ckα and ek2 genes, respectively, were expressed at markedly low levels in the MCF7, HCT116 and HepG2 cells (Fig. 1B) . The mRNA expression levels of ckα2 were as low as 2±1.41, 2±0.71 Table I . ck and ek primer sequences.
PCR Primer name
Primer sequence product size(bp)
F, forward; R, reverse; bp, base pairs; PCR, polymerase chain reaction. and 18±4.24 mRNA copies/ng total RNA, as determined by absolute quantification; whereas ek2β mRNA expression was 10±6.36, 18±4.24 and 1±0.71 mRNA copies/ng total RNA in the MCF7, HCT116 and HepG2 cells, respectively.
In the present study, due to overlapping cDNA sequences, a general ckα primer pair, known as total-ckα and a specific ckα2 primer pair were designed to quantify the mRNA expression levels of the ckα variants in the MCF7, HCT116 and HepG2 cells. The ckα1 mRNA expression levels were quantified only by the absolute quantification strategy. The absolute mRNA copy numbers of the ckα1 variants were determined by calculating the difference between the copy number of the total-ckα and ckα2 variants. Due to the markedly low expression levels of the ckα2 variant detected in all of the cancer cell lines tested, the mRNA copy number of the ckα1 variant was shown as equal to the copy number of total-ckα (Fig. 1B) .
Besides determining the quantification of each ck and ek mRNA variant in various cancer cells, the qPCR approach permits the comparison of mRNA expression levels of all of the ck and ek variants in the same cancer cell line. For the relative quantification strategy, the ckβ gene was chosen as the calibrator and its relative mRNA expression was arbitrarily set at 1.0. The mRNA expression levels of total-ckα, ckα2, ek1, ek2α and ek2β were therefore compared, relative to ckβ (Fig. 2A) . The ek2α variant had the highest mRNA expression levels among ck and ek variants, in MCF7 cells, as determined by absolute quantification, with a difference of 2762 mRNA copies/ng total RNA, as compared with ckβ (Fig. 2B ). This finding is concordant with the 2.9-fold higher expression level of ek2α, as compared with ckβ, as determined by the relative quantification strategy (Fig. 2A) . The mRNA expression levels of ckα1 were slightly lower, as compared with ckβ, in the MCF7 cells with ~248 copies difference between total ckα1 and ckβ mRNA expression levels, as determined by the absolute quantification strategy. In the HCT116 cells, the mRNA expression levels of ckβ were the highest, with 1975±695.93 mRNA copies/ng total RNA. The relative mRNA expression levels of total-ckα were 0.59-fold lower, as compared with ckβ. Conversely, the expression levels of total-ckα were the highest, as compared with the other ck and ek variants, in the HepG2 cells. The expression of total-ckα was 1.26-fold higher, as compared with ckβ; whereas the relative ek1 mRNA expression level was ~50% that of ckβ. The ek2α mRNA expression level was 0.08-fold, as compared with ckβ, which was equal to 111±39.85 mRNA copies/ng total RNA, in the HepG2 cells. The mRNA expression levels of the ckα2 and ek2β variants in the MCF7, HCT116 and HepG2 cells were negligible as compared with ckβ.
Prediction of CpG islands at ck and ek gene promoters.
The presence of CpG islands at the gene promoter region potentially increases the DNA methylation activities, which may affect the expression of ck and ek genes. To examine this possibility, the ckα, ckβ, ek1 and ek2 promoter regions were analysed for the presence of CpG islands. The promoter regions of ckα, ckβ and ek2 were all predicted to contain putative CpG islands (Fig. 3) . This hypothesis was supported by the relatively high GC content (>70%) and an observed/expected ratio of >0.70. An analysis of the ckα gene promoter region predicted two CpG islands located at the 5' upstream regions between -695 and -907 (213 bp) and between -55 and -566 (512 bp). The former CpG island contained 138 CpGs, a GC content of 64.79% and 
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an observed/expected ratio of 0.76, whereas the latter CpG island consisted of 405 CpGs, a GC content of 79.10% and an observed/expected ratio of 0.96. Similarly, two CpG islands were predicted at the gene promoter region of ckβ. The first CpG island region was located between -712 and -988 (277 bp), consisted of 164 CpGs, had a 59.21% GC content and an observed/expected ratio of 0.73. The other CpG island covered a larger region, between -55 and -665 (611 bp), consisted of 437 CpGs with a 71.52% GC content and an observed/expected ratio of 0.94. A 512 bp CpG island between -59 and -570 containing 398 CpGs, with a 77.73% GC content and an observed/expected ratio of 0.80 was predicted in the ek2 promoter region. There were no predicted CpG islands at the 5' upstream region of the ek1 gene. These results indicate that the regulation of ck and ek expression may be affected by DNA methylation at the promoter region. This prompted the exploration into the effects of DNA demethylation on the expression levels of ck and ek mRNA variants.
Effects of TSA treatment on ck and ek mRNA expression profiles. The HDAi TSA was used to investigate the effects of DNA methylation on ck and ek mRNA expression. The expression levels were determined using the absolute quantification strategy, with YWHAZ reference gene used as the internal control. TSA, which indirectly causes DNA demethylation, altered total-ckα, ckβ and ek2α mRNA expression levels in the HepG2 cells (Fig.4) . The mRNA expression levels of total-ckα, which were high in the HepG2 cells, exhibited a significant upregulation in response to TSA treatment, as compared with the control (P<0.05). Conversely, TSA treatment resulted in a substantial downregulation in the mRNA expression levels of ckβ, with a >2-fold decrease to 438±198.01 mRNA copies/ng total RNA, as compared with the control expression of 1059±32.95 mRNA copies/ng total RNA (P<0.05). There were no significant changes to the ek1 mRNA expression levels in the HepG2 cells, in response to the TSA treatment. This observation correlates with the absence of a predicted CpG island in the ek1 promoter region. Notably, the mRNA expression levels of ek2α, which were repressed in the HepG2 cells, exhibited a substantial increase of >8 fold to 744 mRNA copies/ng total RNA, in response to TSA treatment.
Effects of TSA treatment dosage and duration on ek2α mRNA expression. The substantial induction of ek2α mRNA expression in response to TSA treatment, led to further investigations regarding the effects of various TSA concentrations and treatment durations on ek2α expression levels. A TSA concentration as low as 250 nM was able to significantly induce ek2α mRNA expression in the HepG2 cells (Fig. 5) . A dose-dependent increase in the mRNA expression levels of ek2α was observed in response to TSA treatment up to 1000 nM. At 1000 nM TSA, the expression of ek2α was 666±46.73 mRNA copies/ng total RNA, as compared with the control of 101±11.27 mRNA copies/ng total RNA. There were no significant differences in the mRNA expression TSA treatment also induced ek2α mRNA expression, in the HepG2 cells, in a time-dependent manner (Fig. 6) . A significant increase in the mRNA expression levels of ek2α, in response to TSA treatment, was observed throughout the duration tested, starting from 6 h (P<0.05). The highest ek2α mRNA expression levels were detected 18 h post-TSA treatment with 2061 mRNA copies/ng total RNA, as compared with 184 mRNA copies/ng total RNA in the control. The longer treatment durations, >18 h, resulted in a gradual decrease in the mRNA expression levels of ek2α.
Discussion
Two qPCR quantification approaches, absolute and relative, are usually applied to determine the mRNA expression levels of ck and ek variants. Different experimental protocols are required for these approaches and each of them has advantages over the other. Relative quantification takes into account the expression levels of target genes, as well as the reference gene, therefore excluding the need to use a calibration curve. However, the use of a stably expressed reference gene throughout the experiment is required and must be identified prior to quantification. To perform a reliable comparison, the amplification efficiencies of both the target and reference genes must be similar (28) . Normalisation with a suitable reference gene greatly minimises the variation in total RNA input, qPCR efficiencies and sample to sample variation; therefore, producing accurate and reliable results.
Conversely, normalization to a reference gene is not required in the absolute quantification strategy. The absolute quantification approach uses a highly reproducible calibration curve, which is generated using a serial dilution of a standard DNA molecule, such as recombinant plasmid DNA, which was used in the present study. The absolute quantification strategy is dependent on the accuracy of the standard; therefore, similar qPCR efficiencies for both the calibration curve and target gene, as well as the accurate determination of the concentration of the standard, are of critical importance. Absolute quantification allows the absolute copy number of the mRNA transcript to be determined, in contrast to relative quantification which only measures the relative change to the mRNA expression level. A wide dynamic range of the constructed calibration curve, up to a few orders of magnitude, also allows genes that are very lowly expressed to be quantified.
In the present study, quantification of the mRNA expression levels of the ck and ek variants in MCF7, HCT116 and HepG2 cells was determined using both the absolute and relative qPCR approaches, which generated similar results. In relative quantification, application of a mathematical model with a correction for the PCR kinetic efficiency (26) has previously been shown to reflect the actual cell situation, therefore allowing the generation of reliable results similar to absolute quantification (29) . The relative quantification strategy provides a ratio of the expression of the gene of interest, rather than the absolute copy number in a defined concentration of total RNA. In the present study, each ratio was generated based on the expression of total-ckα, ckα2, ckβ, ek1, ek2α and ek2β, normalised to the geometric means of UBC and YWHAZ expression levels. However, a high ratio produced in relative quantification does not necessarily reflect a high expression level of the target gene. Pfaffl (30) stated that these expression ratios are sensitive and dependent on the expression levels of the genes used for normalization. Therefore, the outcomes derived from relative and absolute qPCR strategies are not completely comparable. This may explain the differences observed in the mRNA expression levels of ckβ, ek1, ek2α and ek2β determined using both approaches. For example, the mRNA expression levels of ek2β in the HCT116 cells were shown to be >2-fold higher, as compared with the expression levels detected in the MCF7 cells, as determined by the relative quantification strategy. However, the mRNA expression levels of ek2β were only different by a small number of copies in the HCT116 and MCF7 cells, when the absolute quantification approach was used.
The results obtained from both quantification strategies supported the earlier hypothesis that the mRNA expression levels of each ck and ek variants in MCF7, HCT116 and HepG2 cells varies. Total-ckα mRNA expression was detected in all three cancer cell lines tested. Notably, ckα, which has previously been shown to be overexpressed in breast cancer-derived cell lines (12, 14) , was expressed at lower expression levels in the MCF7 breast cancer cells, as compared with the HepG2 liver cancer cells in the present study. Currently, there have been few comparisons made between ckα and ckβ mRNA expression levels in cancer cells. The present study demonstrated that ckβ transcript expression levels exceed that of total ckα in breast and colon cancer cell lines. This observation is in agreement with a previous qPCR analysis of ckα and ckβ mRNA expression ratios in T47D human breast cancer cells, that showed higher mRNA expression levels of ckβ (10) . The balance of ckα and ckβ mRNA expression levels has also been shown to have a vital role in cancer cell survival (15) .
EK1 protein was previously demonstrated as being uniformly distributed in various human tissues, whereas EK2 was selectively expressed in the kidney, liver, ovary, testis and prostate (6). Tian et al (31) detected significantly higher ek2 mRNA expression levels in the mouse liver, as compared with the kidney and testis. In the present study, ek2β, the splice variant of ek2, exhibited a markedly low mRNA transcript level in all three of the cancer cell lines examined, thus suggesting that transcription of the ek2β gene may be negligible and this isoform may not have a significant role in phosphatidyletanolamine synthesis in these three cancer cell lines.
The present study demonstrated that TSA treatment did not have the same effects on the gene expression of all of the ck and ek variants. This is concordant with previous studies, which showed that inhibition of HDAC activity by HDACi affected only 2-5% of expressed genes in numerous cancer cell lines (32) (33) (34) . The presence of CpG islands was predicted at the promoter regions of ckα, ckβ and ek2α, which may explain the effects of TSA treatment on the expression of these genes. It has previously been stated that 94% of TSA-induced genes have CpG islands at the gene promoter region (35) . It may be hypothesized that TSA influences the gene expressions of ck and ek by DNA demethylation at the methylated CpG islands in the promoter region, as is the case for p16, SALL3 and GATA4 genes (36) .
Treatment with various HDACi, such as vorinostat, in a human myeloma cell line was shown to increase the degree of acetylation and methylation of lysines in histones H3 and H4 at the proximal promoter region of the target gene (37) . Chromatin immunoprecipitation analysis previously detected an accumulation of acetylated histones H3 and H4 at the promoter regions of the upregulated genes post-TSA treatment (38) . Therefore, it may be possible that the elevated ek2α mRNA expression was due to the accumulation of acetylated histones H3 and H4, located around the promoter region, which subsequently induced the expression of ek2α. Furthermore, TSA may also induce the recruitment of euchromatic markers and RNA polymerase II to the transcription factor complex that binds to the promoter, thus facilitating gene transcription (39) .
Previously, magnetic resonance spectroscopy demonstrated that the HDACis LAQ824 and SAHA, increased the cellular levels of PCho in human colon cancer cells and tumor xenografts (40) . The rise in PCho de novo synthesis was shown to be closely associated with an induction of ckα expression. The present study showed that the mRNA expression levels of ckα in HepG2 cells were upregulated in response to TSA treatment, and supported the use of PCho as a potential biomarker to monitor the activities of HDACi.
The downregulation of ckβ expression upon TSA treatment, as observed in the present study, may be the result of either a direct or indirect inhibitory effect. The indirect effect of TSA on HDAC regulated gene transcription may be through specific recruitment of non-histone HDAC targets to various gene regulatory regions (33) . The attenuating effects on ckβ expression may result in a reduction in cellular CK activity and phosphatidylcholine biosynthesis in liver cancer cells. However, the enhanced expression of total ckα by TSA would compensate for phosphatidylcholine biosynthesis which is required for cell proliferation, especially during tumor progression.
The dose-and time-dependent induction of ek2α by TSA is similar to previous reports that showed the variations in TSA dose and treatment duration that altered the expression profile of genes involved in apoptosis and the cell cycle (38, 41) . The mRNA expression levels of genes affected by HDAC inhibition have been shown to increase proportionally with the concentration and treatment duration of HDACi (42) .
The mRNA expression levels of ck and ek variants in MCF7, HCT116 and HepG2 cells were determined and quantified in the present study. Both relative and absolute quantification strategies generated similar mRNA expression patterns. In response to epigenetic drug treatment, TSA upregulated the expression levels of total-ckα and ek2α, but downregulated the expression levels of ckβ. The induction of ek2α by TSA was both concentration-and time-dependent. The effects of TSA may be mediated by the presence of CpG islands in the promoter regions of the affected genes. However, further experiments are required to confirm this assumption. A future aim may be to identify the CpG sites that are responsible for the pronounced effects on ckα, ckβ and ek2α gene expressions in HepG2 cells during TSA treatment.
